Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio di ricerca su quanto bene Concizumab funziona per te se hai l'emofilia A o B con o senza inibitori (Explorer10)

17 settembre 2026 aggiornato da: Novo Nordisk A/S

Studio in aperto che indaga l'efficacia, la sicurezza e la farmacocinetica della profilassi con concizumab nei bambini di età inferiore a 12 anni affetti da emofilia A o B con o senza inibitori

This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use.

Participants will have to inject the study medicine every day under the skin with a pen-injector.

The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for purchase in their country.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

153

Fase

  • Fase 3

Accesso esteso

Non più disponibile al di fuori della sperimentazione clinica. Vedi record di accesso esteso.

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Algiers, Algeria, 16000
        • Haematology and Blood Bank Department
      • Constantine, Algeria, 25000
        • CHU Constantine BEN BADIS/ Hematology department
      • Banja Luka, Bosnia Erzegovina, 78000
        • University Clinical Center of Republic Srpska (545)
      • Tuzla, Bosnia Erzegovina, 75000
        • University Clinical Centre Tuzla
      • Plovdiv, Bulgaria, 4002
        • UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Pediatrics
      • Sofia, Bulgaria, 1527
        • UMHAT Tsaritsa Yoanna - ISUL EAD, Pediatric clinical hematology and oncology
      • Varna, Bulgaria, 9010
        • UMHAT Sveta Marina EAD, Clinic of Pediatric Clinical Hematology and Oncology
    • British Columbia
      • Vancouver, British Columbia, Canada, V6H 3V4
        • BC Children's Hospital
    • Ontario
      • Hamilton, Ontario, Canada, L8N 3Z5
        • McMaster Children's Hospital
      • Tallinn, Estonia, 13419
        • Tallinn Children's Hospital
      • Chambéry, Francia, 73000
        • Centre Hospitalier Metropole Savoie
      • Le Kremlin-Bicêtre, Francia, 94275
        • Ap-Hp-Hopital de Bicetre-1
      • Paris, Francia, 75015
        • AP-HP-HOPITAL NECKER_Service d'hématologie
      • Kanagawa, Giappone, 216-8511
        • St. Marianna University School of Medicine Hospital_Pediatrics
      • Saitama, Giappone, 330-8777
        • Saitama Children's Med Centre_Hematology-Oncology
      • Athens, Grecia, GR-11527
        • Aghia Sophia Childrens' Hospital
      • Thessaloniki, Grecia, GR 54642
        • 'Ippokrateio' General Hospital of Thessaloniki
      • Thessaloniki, Grecia, 54642
        • 'Ippokrateio' General Hospital of Thessaloniki
    • Assam
      • Guwahati, Assam, India, 781032
        • Guwahati Medical College
    • Gujarat
      • Surat, Gujarat, India, 395002
        • Nirmal Hospital Pvt. Ltd.
    • Maharashtra
      • Kolhāpur, Maharashtra, India, 416005
        • SSSH_Dept. of Clinical Haematology & Haemato Oncology
      • Mumbai, Maharashtra, India, 400012
        • Seth GS Medical College & KEM Hospital
      • Mumbai, Maharashtra, India, 400022
        • K.J Somaiya Hospital and Research Centre
      • Mumbai, Maharashtra, India, 400066
        • MCGM - Comprehensive Thalassemia Care
      • Pune, Maharashtra, India, 411004
        • Sahyadri Super Speciality Hospital
    • Odisha
      • Cuttack, Odisha, India, 753007
        • S.C.B. Medical College
    • Rajasthan
      • Jaipur, Rajasthan, India, 302004
        • J K Lon Hospital
    • Uttar Pradesh
      • Noida, Uttar Pradesh, India, 201303
        • Post Graduate Institute of Child Health
    • Uttart Pradesh
      • Lucknow, Uttart Pradesh, India, 226014
        • SGPGI
      • Catania, Italia, 95123
        • A.O.U policlinico "G. Rodolico-San Marco"
      • Florence, Italia, 50134
        • Dipartimento di Ematologia Univ. Firenze
      • Padova, Italia, 35128
        • Azienda Ospedaliera di Padova _
      • Parma, Italia, 43126
        • Azienda Ospedaliera-Universitaria Parma
      • Beirut, Libano, 961
        • Saint George Hospital University Medical Center
      • Tripoli, Libano, 1434
        • Hospital Nini
      • Vilnius, Lituania, LT-08406
        • Centre of Oncology and Hematology, Vilnius University
      • Skopje, Macedonia del Nord, 1000
        • PHI University Clinic for Children's Diseases Skopje
    • Kuala Lumpur
      • Kampung Baru, Kuala Lumpur, Malaysia, 50300
        • Hospital Tunku Azizah
    • Pulau Pinang
      • George Town, Pulau Pinang, Malaysia, 10450
        • Hospital Pulau Pinang
    • Sarawak
      • Kuching, Sarawak, Malaysia, 93586
        • Sarawak General Hospital
    • Terengganu
      • Kuala Terengganu, Terengganu, Malaysia, 20400
        • Hospital Sultanah Nur Zahirah
      • Oslo, Norvegia, 0372
        • Klinisk forskningspost
      • Gdansk, Polonia, 80-952
        • Uniwersyteckie Centrum Kliniczne
      • Lublin, Polonia, 20-093
        • Uniwersytecki Szpital Dzieciecy, Dzial Krwiolecznictwa
      • Warsaw, Polonia, 02-091
        • Uniwersyteckie Centrum Kliniczne WUM
    • Lower Silesian Voivodeship
      • Wroclaw, Lower Silesian Voivodeship, Polonia, 50-556
        • Uniwersytecki Szpital Kliniczny im. J.Mikulicza-Radeckiego
      • Birmingham, Regno Unito, B4 6NH
        • Birmingham Children's Hospital
      • Bristol, Regno Unito, BS2 8BJ
        • University Hospitals Bristol & Weston NHS Foundation Trust
      • London, Regno Unito, WC1N 3HR
        • Great Ormond Street Hospital for Children
      • London, Regno Unito, SE1 7EH
        • Evelina London Children's Hospital - Haemophilia
      • Bucharest, Romania, 022328
        • Clinic of Haematology, Fundeni Clinical Institute
      • Cluj-Napoca, Romania, 400177
        • Spitalul Clinic de Urgenta pentru Copii Cluj Napoca
      • Oradea, Romania, 410469
        • Spitalul Clinic Judetean De Urgenta Bihor
      • Barcelona, Spagna, 08035
        • Hospital Vall d'Hebron
      • Madrid, Spagna, 28046
        • Hospital Universitario La Paz
      • Málaga, Spagna, 29009
        • Hospital Regional Universitario de Málaga
    • Murcia
      • El Palmar, Murcia, Spagna, 30120
        • Hospital Virgen de la Arrixaca - Hematología
    • California
      • San Diego, California, Stati Uniti, 92123
        • Rady Childrens Hosp San Diego
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • University of Colorado Hospital
    • Florida
      • Orlando, Florida, Stati Uniti, 32806
        • Arnold Palmer Children's Hospital
      • Orlando, Florida, Stati Uniti, 32827
        • Nemours Child Orlando Hem/Onc.
    • Georgia
      • Augusta, Georgia, Stati Uniti, 30912
        • Augusta Univ/Childrens Hosp-GA
      • Savannah, Georgia, Stati Uniti, 31404
        • Memorial Health University Medical Center
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60611
        • Childrens Hospital of Chicago
    • Indiana
      • Indianapolis, Indiana, Stati Uniti, 46260
        • Indiana Hemophilia-Thromb Ctr
    • Louisiana
      • New Orleans, Louisiana, Stati Uniti, 70121
        • Ochsner Clinic Foundation
      • New Orleans, Louisiana, Stati Uniti, 70118
        • Children's Hosp-New Orleans
    • Missouri
      • Kansas City, Missouri, Stati Uniti, 64108
        • The Children's Mercy Hospital
    • Nebraska
      • Omaha, Nebraska, Stati Uniti, 68114
        • Children's Nebraska
    • North Carolina
      • Greenville, North Carolina, Stati Uniti, 27834
        • ECU Sickle Cell Comp Clinic
    • Ohio
      • Columbus, Ohio, Stati Uniti, 43205
        • Nationwide Children's Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19134
        • St Christopher Hosp for Child
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37232
        • Monroe Carell Jr. Children's Hospital at Vanderbilt
    • Texas
      • Fort Worth, Texas, Stati Uniti, 76104
        • Cook Children's Hospital-Hematology-Oncology
      • Houston, Texas, Stati Uniti, 77030
        • Texas Children's Hospital_Houston
    • Virginia
      • Charlottesville, Virginia, Stati Uniti, 22908
        • Pediatrics Hematology/Oncology Clinic Battle Building
    • Gauteng
      • Parktown, Johannesburg, Gauteng, Sud Africa, 2193
        • Charlotte Maxeke Johannesburg Academic Hospital
      • Gothenburg, Svezia, 413 46
        • Sahlgrenska US - Koagulationscentrum
      • Bangkok, Tailandia, 10400
        • Ramathibodi Hospital
      • Bangkok, Tailandia, 10330
        • King Chulalongkorn Memorial Hospital_Bangkok_0
      • Bangkok, Tailandia, 10700
        • Siriraj Hospital - Hematology and Oncology
      • Bangkok, Tailandia, 10330
        • King Chulalongkorn Memorial Hospital_Pediatric Hematology-Oncology
    • Mueang Distirct,
      • Ubon Ratchathani, Mueang Distirct,, Tailandia, 34000
        • Sunpasitthiprasong Hospital_Pediatrics Department
      • Adana, Turchia (Türkiye), 01130
        • Acibadem Adana Hastanesi
      • Adana, Turchia (Türkiye), 01130
        • Acıbadem Adana Hastanesi-Hematoloji
      • Izmir, Turchia (Türkiye), 35100
        • Ege Universitesi Tip Fakultesi
      • Izmir, Turchia (Türkiye), 35100
        • Ege Üniversitesi Hastanesi- Hematoloji
      • Samsun, Turchia (Türkiye), 55139
        • Ondokuz Mayis University Medical Faculty Ped. Haematology
      • Samsun, Turchia (Türkiye), 55139
        • Ondokuz Mayıs Üniversitesi Hastanesi - Hematoloji
    • Beşevler/Ankara
      • Ankara, Beşevler/Ankara, Turchia (Türkiye), 06500
        • Gazi University
      • Ankara, Beşevler/Ankara, Turchia (Türkiye), 06500
        • Gazi Üniversitesi Hastanesi- Hematoloji

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino
  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Informed consent/assent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.

  • Diagnosis of congenital severe haemophilia A (FVIII below 1%) or moderate/severe congenital haemophilia B (FIX (coagulation factor IX) below or equal to 2%), or congenital haemophilia with inhibitors.

  • For arm 1 only: Male aged below 12 years of age at the time of signing informed consent.

  • For arm 1 only: Patients with inhibitors (haemophilia A with inhibitors or haemophilia B with inhibitors)

    1. Patients with HAwI (haemophilia A with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
    2. Patients with HBwI (haemophilia B with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
    3. Patients with HBwI regardless of the regimen and duration of previous haemophilia treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products)
  • For arm 1 only: Patients without inhibitors (haemophilia A or haemophilia B)

    1. Patients with historical medical records of at least 52 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products; Surgery related PPX or short-term PPX (e.g., in relation to a severe bleed) is not allowed) during the last year prior to enrolment and with at least 3 documented treated bleeds (For participants less than (<) 2 years of age there is no limitation for number of documented treated bleeds in the medical history) during this period
    2. Patients with historical medical records of a total of at least 26 weeks of PPX (prophylaxis) treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available)
  • For arm 2 only: Male patients (regardless of age) previously treated with concizumab via compassionate use.

Exclusion Criteria:

  • Known or suspected hypersensitivity to study intervention or related products.
  • Known inherited or acquired coagulation disorder other than congenital haemophilia.
  • Ongoing or planned Immune Tolerance Induction treatment.
  • History of thromboembolic disease (aIncludes arterial and venous thrombosis including myocardial infarction, pulmonary embolism, cerebral infarction/thrombosis, deep vein thrombosis, other clinically significant thromboembolic events and peripheral artery occlusion.). Current clinical signs of or treatment for thromboembolic disease. Patients who in the judgement of the investigator are considered at high risk of thromboembolic events (Thromboembolic risk factors could include, but are not limited to, hypercholesterolemia, diabetes mellitus, hypertension, obesity, smoking, family history of thromboembolic events, arteriosclerosis, other conditions associated with increased risk of thromboembolic events).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Concizumab-naïve patients

Concizumab-naïve participants below 12 years of age at the time of consent/assent

Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.

Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose.

Sperimentale: Patients coming from compassionate use

Patients previously treated with concizumab via compassionate use, either on an individual patient basis or through the concizumab compassionate use programme NN7415-4807

Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.

Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Concizumab-naïve pateints - Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of thromboembolic events, reported both separately for inhibitor and non-inhibitor patients and combined
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of hypersensitivity type reactions, reported both separately for inhibitor and non-inhibitor patients and combined
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of injection site reactions, reported both separately for inhibitor and non-inhibitor patients and combined
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of patients who develop antibodies to concizumab - yes/no, reported both separately for inhibitor and non-inhibitor patients and combined
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of patient(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
Lasso di tempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Concizumab plasma concentrations prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Lasso di tempo: Week 32

Measured in ng/mL

Week 32
Peak thrombin generation prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Lasso di tempo: Week 32

Measured in nM

Week 32
Free TFPI concentration prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Lasso di tempo: Week 32

Measured in ng/mL

Week 32
Pre-dose (trough) concizumab plasma concentration (Ctrough), reported both separately for inhibitor and non-inhibitor patients and combined
Lasso di tempo: Prior to the concizumab administration at week 20

Measured in ng/mL

Prior to the concizumab administration at week 20
Maximum concizumab plasma concentration (Cmax), reported both separately for inhibitor and non-inhibitor patients and combined
Lasso di tempo: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20

Measured in ng/mL

From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
Area under the concizumab plasma concentration-time curve (AUC), reported both separately for inhibitor and non-inhibitor patients and combined
Lasso di tempo: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20

Measured in ng*hr/mL

From 0 to 24 hours where 0 is the time of the concizumab dose at week 20

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

24 marzo 2022

Completamento primario (Effettivo)

21 aprile 2026

Completamento dello studio (Stimato)

2 novembre 2029

Date di iscrizione allo studio

Primo inviato

15 novembre 2021

Primo inviato che soddisfa i criteri di controllo qualità

15 novembre 2021

Primo Inserito (Effettivo)

26 novembre 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

17 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • NN7415-4616
  • U1111-1247-7330 (Altro identificatore: World Health Organization (WHO))
  • 2020-000504-11 (Numero EudraCT)
  • jRCT2031220097 (Identificatore di registro: JAPIC)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .